Details

Autor(en) / Beteiligte

• Nitta, Kyoko
• Nagai, Takako
• Mizunuma, Yuiko
• Kitada, Munehiro
• Nakagawa, Atsushi
• Sakurai, Masaru
• Toyoda, Masao
• Haneda, Masakazu
• Kanasaki, Keizo
• Koya, Daisuke

Titel

N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m 2

Ist Teil von

• Clinical and experimental nephrology, 2019-08, Vol.23 (8), p.1004

Ort / Verlag

Japan

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• A biomarker, by which we can predict alterations of renal function in normoalbuminuric diabetic patients, is not available. Here, we report that endogenous anti-fibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) represents a potential biomarker to predict alterations in eGFR in normoalbuminuric diabetic patients. We analyzed 21 normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m and measured AcSDKP levels in first morning void urine. We divided patients into two groups based on the median values: low or high urinary AcSDKP groups (uAcSDKP/Cr or uAcSDKP/Cr ). At baseline, no significant differences in sex, age, HbA1c, BMI, serum creatinine levels, etc., were observed between the two groups. During ~ 4 years, the alteration in eGFR [ΔeGFR (ΔeGFR observational periods)] was significantly stable in uAcSDKP/Cr group compared with uAcSDKP/Cr group over time (P = 0.003, χ  = 8.58). We also evaluated urine kidney injury molecule-1 (uKim-1) levels and found that ΔeGFR was also stable in low uKim-1 group compared with high uKim-1 group over time (P = 0.004, χ  = 8.38). Patients who fulfilled the criteria for both uAcSDKP/Cr and uKim-1 exhibited stable ΔeGFR (P < 0.001, χ  = 30.4) when compared to the remaining patients. Plasma AcSDKP (P = 0.015, χ  = 5.94) and urine β2-microglobulin (P = 0.038, χ  = 4.31) also display weak but significant predictor of ΔeGFR as well. AcSDKP represents a potentially useful biomarker to predict alterations in the renal function of patients with diabetes presenting normoalbuminuria.